Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Other Operating Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Operating Expenses for 4 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • Quarterly Other Operating Expenses rose 754.99% to $6.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Dec 2025, up 17.93% year-over-year, with the annual reading at $6.8 million for FY2025, 2.64% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $6.8 million at Century Therapeutics, up from $4.2 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $13.1 million in Q4 2023, with the low at $99000.0 in Q2 2023.
  • Average Other Operating Expenses over 4 years is $4.5 million, with a median of $2.5 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses tumbled 68.25% in 2024, then surged 754.99% in 2025.
  • Over 4 years, Other Operating Expenses stood at $10.0 million in 2022, then skyrocketed by 31.45% to $13.1 million in 2023, then crashed by 68.25% to $4.2 million in 2024, then surged by 62.07% to $6.8 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $6.8 million, $4.2 million, and $791000.0 for Q3 2025, Q4 2024, and Q3 2024 respectively.